Clinical Trials Logo

IDH1 Mutation clinical trials

View clinical trials related to IDH1 Mutation.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04056910 Completed - Clinical trials for Advanced Solid Tumor

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

Start date: September 20, 2021
Phase: Phase 2
Study type: Interventional

In this study, response to treatment and (progression free and overall) survival will be described and safety events of ivosidenib in combination with nivolumab will be summarized in patients with advanced solid tumors (nonresectable or metastatic) or enhancing gliomas.

NCT ID: NCT03914742 Completed - Clinical trials for Recurrent Glioblastoma

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Start date: January 3, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and how well BGB-290 and temozolomide work in treating patients with gliomas (brain tumors) with IDH1/2 mutations that have come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating patients with recurrent gliomas.